346 results about "Drug toxicity" patented technology

The present invention generally relates to a combination of the fields of tissue engineering, drug discovery and drug development. It more specifically provides new methods and materials for testing the efficacy and safety of experimental drugs, defining the metabolic pathways of experimental drugs and characterizing the properties (e.g., side effects, new uses) of existing drugs. Preferably, evaluation is carried out in three-dimensional tissue-engineered systems, wherein drug toxicity, metabolism, interaction and/or efficacy can be determined.

Nucleic acid drug carriers comprise a nucleic acid carrier complexed with a drug, wherein the nucleic acid carrier and the drug are associated non-covalently, and optionally other agents such as spacer, transfection agents, and targeting agents. The nucleic acid drug complex are discovered to have permissive or refractory uptake depending on many factors including cell type, proliferation rate, among others. The refractive uptake of the nucleic acid drug complex are shown to be useful in the nucleic acid targeting of drugs, both in vitro and in vivo. Novel drug compositions are disclosed that effectively reduce the toxicity of drugs while maintaining drug activity and enhancing a drug's therapeutic index.

A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.

The present invention identifies and quantifies changes in gene expression associated with non-small cell lung cancer NSCLC by examining gene expression in tissue from normal lung and diseased lung. The present invention also identifies and quantifies expression profiles which serve as useful diagnostic markers as well as markers that are useful to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

A well-based flow system for cell culture is described which provides for flow of culture containing compounds for drug screening to be exposed to cells seeded on a membrane. The flow of medium may be planar or radial and means are provided for the removal of waste media through fluid outlets in fluid communication with the assay well plates through conduits. Methods of using the system for cell culture and drug toxicity screening are also provided including coculturing cells such as hepatocytes, stem cells, fibroblasts and smooth muscle cells and selectively exposing cells to test compounds.

The invention belongs to the new technical field of a drug preparation and in particular relates to a precursor liposome containing a glycyrrhetinic acid and a method for preparing the same. The precursor liposome containing the glycyrrhetinic acid consists of glycyrrhetinic acid, phospholipids, cholesterol, a surfactant and a water-soluble material; a suspension solution of the glycyrrhetinic acid liposome is prepared by an ethanol injection method or a thin-film dispersion method; and solid liposome powder is prepared by a freeze drying method or a spray drying method. The precursor liposome has simple process and good repeatability, is suitable for industrialized production; through drug administration by intravenous injection, the precursor liposome has long-circulating function, can remarkably reduce the toxicity of drug and achieve the function of prolonging the drug effect; and through oral administration, a solid preparation of the liposome can increase absorption and improve bioavailability by three to five times.

The invention provides a semi-contact under-oil continuous droplet sample applying and liquid adding method, which is suitable for sequentially operating a droplet array system. According to the method, the distance between the pointed end of a capillary tube sample applying needle and the lower surface of a micro-hole (or a generated droplet) is controlled accurately, and the affinity or interface tension interaction between the droplet and the surface (or the generated droplet) is utilized, so that rapid and reliable continuous droplet sample applying or continuous liquid adding is realized, and the problem of cross infection during sample applying is solved effectively. The method is suitable for biochemical analysis screening researches such as high-flux medicament screening, protein crystallization condition screening, enzyme kinetics research and drug toxicity determination.

The invention provides the appraisal and selective method for the antineoplastic drug based on the cell micrograph information, which uses a sort of selection and appraisal hardware system to appraisal and select the antineoplastic drug by different fluorescence dye marking and measuring the multicellular parameter change in cell. The hardware system is made up of the high precision electric hydrous platform, the fluorescence vision system, the image collecting and processing system and working station. The diacetoxyl fluoresceine dyeing measures the active cell number; the double dyeing method of Hoechst33342 and iodized pyridine appraise the drug inducing the cell die; the three dyeing method of FDA, Hoechst33342 and PI analyzes the die mode induced by drug. The invention can measure at least two kinds of single cell or cell subgroup which expresses different drone cell organ. The method is in reason and can be used in study of drug action mechanism and selecting the high hedonic drug and toxicity analyzing, which can be used in selecting drug and appraising the drug toxicity.

The invention relates to application of levorotatory oxiracetamto to the field of pharmacy, and specifically relates to application of levorotatory oxiracetamto preparation of medicaments for preventing or treating cognitive dysfunction. According to the invention, levorotatory oxiracetamto with a purity higher than 99.3% is used as a material, so that hidden trouble of drug toxicity caused by invalid ingredients in a medicament is eliminated to further ensure medications safety. In addition, levorotatory oxiracetamto is a single active ingredient in the medicament of the invention, so that medicament quality is easier to control, and a curative effect is more obvious.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]:wherein R represents:or a pharmaceutically acceptable salt thereof.Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.

The invention provides an animal-derived food pathogen identification and drug-resistant and toxic gene detection composite chip. The invention provides a probe for identifying the animal-derived food pathogen, the pathogen drug-resistant gene and/or drug toxicity gene. The probe consists of single-chain DNA (deoxyribonucleic acid) molecules shown by the sequence 1 to sequence 171. Experiment results show that the animal-derived food pathogen identification and drug-resistant and toxic gene detection composite chip provided by the invention can effectively achieve the integral goal of simultaneously identifying the bacteria, the toxicity of the bacteria and the drug-resistant gene.

This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, by reducing chemotherapy-related toxicity to a level that allows the chemotherapeutic drug to be used in humans.

The invention belongs to a pharmaceutical composition, in particular a pharmaceutical composition for treating xerophthalmia. The pharmaceutical composition provided by the invention is prepared from effective amounts of radix rehmanniae, figwort, ophiopogon root, dendrobium, rhizoma anemarrhenae, radix trichosanthis, chrysanthemum, mulberry leaf, pipewort, radix sileris and other raw medicines. The invention solves the problems of short action time, limited treatment, poor treatment effect and the like in the prior art. The pharmaceutical composition has the advantages of small drug toxicity, obvious treatment effect and the like.

The invention provides intravenous nanomicelle agents of vinca alkaloids antitumor drug, it contains an effective dose for treating of vinca alkaloids antitumor drug (vinblastine and vincristine or vindesine), macrogol derivatization phospholipid, and the pharmaceutical acceptable adjuvants. Its preparation is to pack the drug in the formative nanomicelle agents, prepare and make the intravenous nanomicelle agents of vinca alkaloids antitumor drug. Vinca alkaloids antitumor drug and macrogol derivatization phospholipid form into a very uniform size nanomicelle. In micelles, polyethylene glycol molecule and hydrophobic core for drug packing form a hydrophilicitious inhibitory coating, avoid the drugs contact with the protein such as enzymes in the blood and identified and phagocytized by the endothelial system in vivo, phagocytosis, the cycle time of micellar in vivo is extended. In addition, the micellar drug also increases the storage stability and the effect on the tumor of the drug and reduces drug toxicity.

Methods for treating diseases in humans and vertebrate animals are provided using competitive antagonists of cellular metabolites combined with a protective agent for protecting host cells from toxic effects of the drugs. Also provided are kits comprising competitive antagonists and suitable protective agents. In addition, screening methods for identifying competitive antagonists, protective agents and potentiating agents, for use according to the methods of the invention, are provided.

Cepharanthine is used as effective component in preparing medicine for resisting SARS virus. Within the safe dosage range, the present invention has high inhibition rate to SARS virus and powerful effect of preventing SARS virus infection. The medicine can alleviate the syndromes of SARS patient and has fast after cure, less toxicity, high stability and other advantages.

The invention discloses a method for quantitatively evaluating medicament toxicity by using metabonomic technology, which is characterized by comprising the following steps: comprehensively and quantitatively measuring small molecule compounds in a biological sample by using the measuring technology based on mass spectrum, nuclear magnetic resonance and the like, then establishing a multi-dimensional spatial mathematical model by adopting a multi-variable data processing method, calculating a relative distance between an administration group and a control group and taking the relative distance as a quantitative index for evaluating the medicament toxicity so as to solve the difficult problem that the medicament toxicity evaluation lacks the quantitative evaluating index. Compared with the conventional toxicity evaluating method, the method has the advantages of wide application, sensitivity, simple and convenient sampling, no harm to the body, and capability of reflecting the toxicity function more comprehensively, and providing a comprehensive and reliable quantitative evaluating method for toxicity evaluation in new medicament research and development and pharmacologic research.

The invention relates to the technical field of drugs, and especially relates to an insulin nanoparticle and a preparation method thereof. The preparation method comprises the following steps: preparation of an insulin ion pair compound and preparation of the insulin nanoparticle. According to the insulin nanoparticle of the invention, the entrapment rate and the drug loading are high, the particle size distribution is uniform, and a certain slow releasing effect is possessed, so drugs can be effectively prevented from being degraded by proteases, the stability of the drugs can be increased, and a case that the drugs permeate a biomembrane is promoted, thereby curative effects of the drugs are improved, the toxicity of the drugs is reduced, the biological utilization degree of the drugs is increased, and the insulin nanoparticle is suitable for various administration approaches of the drugs; preparation conditions are mild, no violent conditions of high temperature, and high speed shearing force or the like are needed, so the biological activities of the drugs can be guaranteed; and a surfactant Cremophor EL used in the preparation process can inhibit P-glycoprotein, so the permeability of the drugs going through cell membranes is improved, and the absorption of the drugs going through intestinal tract walls to enter blood is increased.

The invention provides an externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and a preparation method thereof. The medicine is prepared by 25 types of medicinal materials such as radix aconiti preparata, wild aconite root, nux vomica (processed), epimedium, achyranthes root, notopterygium root, cyrtomium fortunei, phellodendron, zaocys dhumnade, hairy antler, dipsacus root, dark plum, asarum, Chinese ephedra, cassia twig, safflower, acanthopanax, honeysuckle, earth worm, loranthus, licorice, drynaria (scald), anisetree bark, myrrh gum (processed) and red ginseng. The medicine links closely with pathogen and pathogenesis of a disease and a plurality of medicines are compatible reasonably, thus expelling wind and clearing away cold as well as activating meridians to stop pain. As an externally used cataplasm, the medicine is taken through skin, thus avoiding the irritation of an oral preparation to gastrointestinal tract; in addition, relatively slow percutaneous absorption process inevitably greatly mitigates drug toxicity to the whole body. Neither skin sensibility nor skin irritation occurs. Therefore, the transdermal drug delivery of new preparation improves the safety of medicine taking to a certain extent and provides new choices for safe clinical medicine use.